HYQURE Biotech

HYQure Biotech relies on international compliance standards, leverages excellent quality and technical strength, and has built a one-stop Biosafety service platform focusing on large molecule drugs and CGT drugs. It has passed the EU QP, CNAS, and ISO9001 audit certifications, meeting the strict requirements of global regulatory agencies such as NMPA, FDA, and EMA, providing reliable assurance for innovative pharmaceutical companies. HYQure Biotech has served 300+ biopharmaceutical companies, with rich experience in project and application, and has provided key support for more than 80 clinical and marketing applications of biopharmaceuticals, including more than 40 Sino-US dual-reporting projects, offering services such as virus clearance validation, cell bank identification, commercial batch release, replication-competent virus (RCL, rcAAV, RCR, etc.) testing, and services such as HCD and HCP kit and testing.